Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

There's robust potential in US tech, pharma and Qantas, while red flags exist in a number of ASX companies that make them ...

The Department of Health and Human Services says Vertex is 'grasping at straws' in a lawsuit challenging the agency’s ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

In a report released on January 13, David Li from Bank of America Securities maintained a Buy rating on Zai Lab (ZLAB – Research Report), with ...

$358 billion in 2022 revenue. 1,187,266 jobs created. And 5,000 examples of how to scale your business. Nowhere else will you find a list of companies with a greater impact on the U.S. economy ...